Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Trial Profile

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Cardiovascular disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DIVE
  • Most Recent Events

    • 09 Aug 2016 Status changed from recruiting to completed.
    • 06 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.
    • 12 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top